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During 1996–1997, a new Vibrio vulniﬁ  cus biotype 3, 
which caused severe soft tissue infection after ﬁ  shbone 
injury, emerged in Israel. We conducted a follow-up study 
from 1998 through 2005 to assess changing trends, out-
comes, and molecular relatedness of the implicated strains. 
A total of 132 cases (71% conﬁ  rmed and 29% suspected) 
of V. vulniﬁ  cus biotype 3 infection were found. Most infec-
tions (95%) were related to percutaneous ﬁ  sh  exposure, 
mainly tilapia (83%) or common carp (13%). Bacteremia, al-
tered immune status, and history of ischemic heart disease 
were identiﬁ  ed as independent risk factors for death, which 
reached a prevalence of 7.6%. Pulsed-ﬁ  eld gel electropho-
resis patterns of strains from 1998 through 2005 and from 
1996 through 1997 showed a high degree of homogeneity 
and were distinct from those of V. vulniﬁ  cus biotype 1. Infec-
tions caused by V. vulniﬁ  cus biotype 3 continue to affect the 
public’s health in Israel. 
V
ibrio vulniﬁ  cus, a gram-negative bacterium of the fam-
ily Vibrionaceae, is a worldwide inhabitant of salt wa-
ter (1–3). V. vulniﬁ  cus biotypes 1 and 2 are capable of caus-
ing severe human infection, including necrotizing fasciitis 
and septicemia; the death rate is substantial (4–6). Persons 
with chronic liver disease, particularly liver cirrhosis, are 
more prone to developing infection and at greatest risk for 
an adverse outcome (7,8). Other predisposing factors are 
iron overload and hemochromatosis and immunosuppres-
sion caused by steroid treatment, malignancy, HIV infec-
tion, renal failure, and organ transplantation (1,9,10). 
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During 1996–1997, a new biotype, V. vulniﬁ  cus bio-
type 3, emerged as a cause of severe soft tissue infection 
and bacteremia in Israel (11,12). Several important features 
differentiate the illness caused by the new V. vulniﬁ  cus bio-
type from previously described V. vulniﬁ  cus infections. 
First, a new vector, a pond ﬁ  sh (tilapia) grown in fresh wa-
ter, has been associated with V. vulniﬁ  cus infection. Sec-
ond, infection is caused by direct injury from the ﬁ  sh back-
bone while purchasing, cleaning, or handling the live ﬁ  sh, 
as opposed to contamination of a prior injury by immersion 
in seawater or ingestion of contaminated seafood. Bacterio-
logically, the new V. vulniﬁ  cus biotype differs from other 
V. vulniﬁ  cus strains by its biochemical features (salicin-, 
cellobiose-, citrate-, and lactose-negative, plus delayed re-
action for o-nitrophenyl-β-D-galactopyranoside [ONPG]). 
These biochemical differences initially prevented correct 
identiﬁ  cation of the strain by routine laboratory methods 
(11,12). Furthermore, molecular analyses using several 
methods have shown that V. vulniﬁ  cus biotype 3 is geneti-
cally distinct from biotypes 1 and 2 (11–15). Bisharat et al. 
suggested that biotype 3 is a recombinant clone that may 
have emerged as a result of hybridization of 2 V. vulniﬁ  cus 
populations (14). Currently, biotype 3 is geographically 
restricted to Israel; biotypes 1 and 2 have a worldwide dis-
tribution (16).
The 1996–1997 Israeli cluster involved 62 persons, 
with a slight male predominance (58%) and a median age 
of 56 years. Although no deaths were reported, 41 persons 
(66%) had conditions that required surgical debridement, 
1 had total limb amputation, and 7 had ﬁ  nger amputations 
(11). A new, aggressive, live-ﬁ  sh marketing initiative in the 
northern part of Israel was implicated in the outbreak, and 
the outbreak was followed by new instructions from the 
Israeli Ministry of Health that recommended selling only 
precleaned, ice-chilled tilapia (17).
We studied the epidemiology and the trends in illness-
es associated with the new V. vulniﬁ  cus biotype 3 during a 
7-year period (1998–2005) following the initial 1996–1997 
cluster. Our study assesses the effects of infection, risk fac-
tors for death, possible spread to other ﬁ  sh species, and mo-
lecular relatedness of the V. vulniﬁ  cus biotype 3 strain.
Methods
Clinical Data
Clinical data were obtained from the records of the In-
fectious Diseases Department, Epidemiology Unit, Israel 
Ministry of Health, Jerusalem. Subdistrict health ofﬁ  ces 
reported data collected from persons with V. vulniﬁ  cus 
infections; a standardized questionnaire was used. Inves-
tigation was initiated after passive reporting from primary 
physicians who treated patients with suspected V. vulniﬁ  -
cus infection or when clinical isolates were positively iden-
tiﬁ  ed as V. vulniﬁ  cus biotype 3 by the Vibrio Reference 
Laboratory in the Government Central Laboratories, Israel 
Ministry of Health, Jerusalem. The data collected were 
patient’s age, sex, and place of residence; underlying dis-
eases; circumstances of exposure and type of ﬁ  sh involved; 
time lapse from exposure to seeking treatment in the emer-
gency department; site of infection; length of hospitaliza-
tion; clinical symptoms; source of isolation; antimicrobial 
drug treatment; and outcome.
Cases were classiﬁ  ed as laboratory-conﬁ  rmed when a 
patient with suggestive history had V. vulniﬁ  cus or V. vul-
niﬁ  cus biotype 3 isolated from blood or soft tissue or as 
suspected when a patient had suggestive history without 
positive cultures. Suggestive history was considered to be 
the development of soft tissue infection or septicemia af-
ter recent (within 7 days) ﬁ  sh exposure or immersion in a 
water pool. 
Source of Isolates and Laboratory Diagnosis
Initial identiﬁ  cation of V. vulniﬁ  cus was performed in 
the microbiology laboratories of hospitals where infected 
patients had been admitted, using the API 20E strip (bio-
Mérieux, Marcy-l’Etoile, France). The laboratories submit-
ted the isolates for conﬁ  rmation and further identiﬁ  cation 
to the Vibrio Reference Laboratory, Government Central 
Laboratories in Jerusalem. Identiﬁ  cation of V. vulniﬁ  cus 
biotype 3 was performed solely in this laboratory by using 
biochemical tests (failure to ferment citrate, lactose, sali-
cin, cellobiose, and a negative test result for ONPG).
Random isolates were also submitted for molecular 
analysis of the cytotoxin-hemolysin gene. This test was 
developed in the Vibrio Reference Laboratory and can dif-
ferentiate between V. vulniﬁ  cus biotype 3 and biotypes 1 
and 2 by demonstrating the unique restriction fragment 
length polymorphism (RFLP) patterns of biotype 3 (Fig-
ure 1). Brieﬂ  y, the V. vulniﬁ  cus cytotoxin-hemolysin gene 
(vvhA) is ampliﬁ  ed from crude bacteria lysate (boiling a 
loop full of bacteria suspended in 100 μL Tris-EDTA buf-
fer for 10 min) using primers with the sequences RRCTH 
5′-CAGCTCCAGCCGTTAACCGAACCACCCGC-3′ 
and LCTH 5′-TTCCAACTTCAAACCGAACTATGAC-
3′. This step is followed by RFLP analysis. For the enzy-
matic restriction reaction, 2 μL of the PCR-ampliﬁ  ed DNA 
was added to a reaction mixture to give a ﬁ  nal volume of 
20 μL, according to the manufacturer’s instructions (New 
England Biolabs, Ipswich, MA, USA), in 2 separate reac-
tions. The restricted DNA was separated by electrophoresis 
in a 2% gel that was stained with ethidium bromide and 
visualized for the speciﬁ  c biotype 3 restriction patterns. Re-
striction sites for 2 enzymes, KpnI and PstI, existed in the 
sequence of vvhA of V. vulniﬁ  cus biotype 3 but not in the 
corresponding vvhA gene of biotypes 1 and 2 (Figure 1).
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Molecular Subtyping 
Twenty randomly selected laboratory-conﬁ  rmed iso-
lates of V. vulniﬁ  cus biotype 3 from study years (1998–
2003) plus 4 retrospective isolates from 1997 were sent 
to Centers for Disease Control and Prevention (CDC), At-
lanta, Georgia, USA, for molecular subtyping. The isolates 
were recovered from the blood or wound sites of patients 
with a history of exposure to various ﬁ  sh. An additional 
isolate was recovered from the remnants of a tilapia ﬁ  sh 
found in the refrigerator of 1 of the infected patients (the 
ﬁ  sh remnants were diced and inoculated onto Vibrio-selec-
tive agar with and without enrichment). These 25 isolates 
were available for further molecular studies. Eight submit-
ted human V. vulniﬁ  cus biotype 1 isolates stored at CDC 
were used for comparison.
V. vulniﬁ  cus isolates were subtyped by pulsed-ﬁ  eld gel 
electrophoresis (PFGE) in accordance with the PulseNet 
protocol for V. cholerae (18) using Sﬁ  I for primary enzyme 
digestion with 1 modiﬁ  cation: thiourea (Sigma-Aldrich, St. 
Louis, MO, USA) was routinely added to the electropho-
resis running buffer at a ﬁ  nal concentration of 50 μmol/L
(19) to prevent DNA degradation, which was commonly 
found during the initial runs. All DNA ﬁ  ngerprints were 
captured using a Gel Doc EQ system (Bio-Rad, Hercules, 
CA, USA). The PFGE ﬁ  ngerprints were analyzed in BioN-
umerics, version 4.0 (Applied Maths, Sint-Martens-Latem, 
Belgium). Gels were normalized by aligning the bands of 
the PulseNet universal standard Salmonella enterica sero-
type Braenderup (H9812) placed in every ﬁ  fth lane on the 
gels (20). Dendrograms were made of the similarities of 
the DNA ﬁ  ngerprints by using the Dice similarity coefﬁ  -
cient and unweighted pair group method with averages (un-
weighted pair group method with arithmetic mean) clus-
tering. An optimization of 1.5% and tolerance window of 
1.5% were used. The 25 isolates sent to CDC as described 
above were submitted for susceptibility tests using the E-
test method according to Clinical Laboratory Standards In-
stitute standards for Enterobacteriaceae (21).
Statistical Methods
Proportions were compared by using the Fisher exact 
test or the χ2 test, and continuous variables were compared 
by using the Kruskal-Wallis test. Variables associated with 
death at the 0.05 signiﬁ  cance level were entered into a step-
wise forward logistic regression model for mortality rate. 
Analyses were performed by using SPSS version 15 soft-
ware (SPSS, Inc., Chicago, IL, USA).
Results
A total of 134 cases of V. vulniﬁ  cus infection were 
identiﬁ  ed during the 8-year study period from 1998 through 
2005 (Figure 2). Most cases (96, 71.6%) were laboratory-
conﬁ  rmed; 70 (52%) were submitted to the Vibrio Refer-
ence Laboratory and identiﬁ  ed as V. vulniﬁ  cus biotype 3. 
PCR-RFLP analysis performed on 34 of these 70 isolates 
(49%) showed the unique KpnI, PstI pattern. Two patients 
with laboratory-conﬁ  rmed V. vulniﬁ  cus biotype 3 infection 
were excluded from further analyses because clinical data 
were missing. The median age of the remaining 132 pa-
tients was 66 years (mean 58.9 years, range 10–93 years) 
(Figure 3). Overall, infection rates for women were only 
slightly higher than those for men (1.1:1); this predomi-
nance increased in those >70 years of age (1.7:1). The sites 
of V. vulniﬁ  cus isolation included wounds in 61 patients 
(65% of 94 patients with laboratory-conﬁ  rmed infection), 
blood in 24 (26%), or both in 7 (7%). The source was not 
recorded in 2 patients.
Clinical characteristics of the patients and outcomes 
are summarized in Table 1. Compared to patients with 
laboratory-conﬁ  rmed infection, patients with suspected in-
fection were more likely to be men, with a longer incuba-
tion period after exposure, less severe clinical symptoms, a 
shorter hospitalization time, and a more favorable outcome. 
Information regarding the type of exposure was available 
for 93 patients. Most of these patients (75, 81%) were in-
jured while purchasing or preparing ﬁ  sh for cooking. Fish 
were purchased from ﬁ  sh stores (52, 56%), mobile selling 
units (9, 10%), or stands near ﬁ  shponds (14, 15%). Other 
types of exposures included involvement in ﬁ  sh marketing 
(14, 15%), either in selling (11/14) or cleaning the ﬁ  shponds 
(3/14). One person was infected after ﬁ  shing at a ﬁ  shpond. 
Four persons had no connection to the pond ﬁ  sh industry. 
Three persons with suspected infection became ill after ﬁ  sh-
ing in the Sea of Galilee, and 1 with laboratory-conﬁ  rmed V. 
  Emerging Infectious Diseases • www.cdc.gov/eid • Vol. 14, No. 12, December 2008  1877 
Figure 1. PCR restriction fragment length polymorphism of Vibrio vulniﬁ  cus cytotoxin gene vvhA. A) PCR amplicon of vvhA gene restriction 
digested with B) PstI or C) KpnI. Gel shows molecular size standards (M) and V. vulniﬁ  cus biotype 3 (lanes 1–3) and biotype 1 (lane 4).RESEARCH
vulniﬁ  cus biotype 3 infection reported immersion in a natu-
ral spring near Jerusalem with an open wound. Most of the 
injuries affected the hands; only 9 affected the legs. 
Most of the infections (74%) occurred in the warm 
months of the year between June and November (Figure 4). 
Most patients resided in northern Israel, where freshwater 
ﬁ  sh aquaculture takes place. Only 6 patients lived in other 
areas of Israel (3 in the central part, 2 in the southern part, 
and 1 near Jerusalem). A total of 104 patients provided de-
tails regarding ﬁ  sh exposure. Tilapia (St. Peter’s ﬁ  sh) was 
the primary ﬁ  sh involved in 86 of these cases (83%), com-
mon carp (Cyprinius carpio) in 14 cases (13%), and both in 
2 cases (2%). Two other patients reported exposure to salt-
water ﬁ  sh: gilt-head sea brim (Sparus aurata) that was pur-
chased in a ﬁ  sh store (laboratory-conﬁ  rmed infection) and 
common gray mullet (Mugil cephalous) that was purchased 
at a ﬁ  sh stand near a ﬁ  shpond (suspected infection).
Course and Outcome
A total of 124 patients (94%) were hospitalized for a 
mean duration of 10.9 days (median 9 days, range 2–50 
days). Information regarding treatment with antimicrobial 
drugs was available for 112 patients and included a vari-
ety of regimens. The most frequent regimens among these 
patients included only a single drug, usually ampicillin-
clavulanate (47 patients, 42%), doxycycline (27, 24%), and 
ceftriaxone (6, 5%). Combinations of drugs were also used 
and included third-generation cephalosporins (ceftriaxone 
or ceftazidime) plus doxycycline (18, 16%), third-genera-
tion cephalosporins plus ampicillin-clavulanate (3, 3%), or 
doxycycline plus ampicillin-clavulanate (8, 7%). 
Ten patients (7.5%) died and 9 (6.8%) underwent am-
putation of ﬁ  ngers or part of the arm (7 patients) or a leg 
(2). Two of the patients who underwent amputation subse-
quently died. Seven of the patients who died (70%) were 
>70 years of age, 2 were in their 50s, and 1 was in his 60s. 
All patients who died or underwent amputation had labora-
tory-conﬁ  rmed infection. 
Ninety patients with laboratory-conﬁ  rmed infections 
were included in the analyses of risk factors associated 
with death. Factors that were signiﬁ  cantly associated with 
death by a univariate analysis are outlined in Table 2. We 
could not show that any of the antimicrobial drug regimens 
inﬂ  uenced outcomes. Variables associated with death were 
entered into a stepwise forward logistic regression model. 
All initially entered variables remained in the model as in-
dependent predictors of a fatal outcome: presence of bacte-
remia (odds ratio [OR] 6.03, 95% conﬁ  dence interval [CI] 
1.2–30.8, p = 0.031), altered immune status (OR 6.7, 95% 
CI 1.1–40.8, p = 0.038), and history of ischemic heart dis-
ease (OR 15, 95% CI 2.5–91.1, p = 0.003) (p value for the 
model <0.001). When septic shock was added, only sep-
tic shock (OR 24.4, 95% CI 4.3–140.2, p<0.001) and his-
tory of ischemic heart disease (OR 9.7, 95% CI 1.3–72.7, 
p = 0.027) remained in the model (p value for the model 
<0.001). The model did not change when adjusted for age.
Antimicrobial Drug Susceptibility Tests
V. vulniﬁ  cus isolates were susceptible to all antimicro-
bial agents tested by criteria for Enterobacteriaceae. The 
MIC ranges for ampicillin were 0.5–1.0 μg/mL; cephalot-
hin, 4–8 μg/mL; chloramphenicol, 0.5–0.75 μg/mL; cipro-
ﬂ  oxacin, 0.012–0.023 μg/mL; kanamycin, 4–16 μg/mL; 
nalidixic acid, 0.25–1 μg/mL; streptomycin, 8–16 μg/mL; 
tetracycline, 0.5–7.5 μg/mL; and trimethoprim-sulfame-
thoxazole, 0.064–0.094 μg/mL. 
Molecular Subtyping
Analysis of the PFGE subtyping results from 25 iso-
lates (21 isolates from 1998 through 2003, 4 isolates from 
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Figure 2. Annual distribution of laboratory-conﬁ  rmed and suspected 
Vibrio vulniﬁ  cus biotype 3 infections.
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Figure 3. Age distribution of patients with laboratory-conﬁ  rmed and 
suspected Vibrio vulniﬁ  cus biotype 3 infections.Molecular Subtyping of V. vulniﬁ  cus, Israel
1997) showed that the selected isolates represented 18 
unique but similar (>88% pattern similarity; 1–3 fragment 
differences) PFGE ﬁ  ngerprint patterns regardless of the 
type of ﬁ  sh exposure (tilapia vs. carp) and year of isolation 
(Figure 5). A tilapia isolate from 2003 generated an Sﬁ  I 
PFGE pattern, which was indistinguishable from the PFGE 
patterns of 3 patient isolates (1 from 2002, 2 from 2003) 
with reported exposure to tilapia from wound sites. When 
compared with biotype 1 strains reported from the United 
States, the biotypes separated into 2 distinct clusters with 
≈70% pattern similarity (Figure 5). 
Discussion
Our study showed that infections caused by V. vul-
niﬁ  cus biotype 3 continued to occur after the initial cluster 
during 1996–1997, with an average of ≈16 cases annually. 
Although the annual rate of infection during 1998–2005 
was half the rate of infection during 1996–1997 (62 cases) 
(11), outcomes were more grave. Our study found that 10 
persons (7.6%) died; no deaths were reported during the 
1996–1997 outbreak (11). Possible explanations for this 
disparity could be that patients in our study were older 
(median age 66 vs. 56 years, respectively) with a higher 
proportion of laboratory-conﬁ  rmed infections (70.1% vs. 
53%, respectively). We have shown that patients without 
laboratory conﬁ  rmation had a much milder form of the dis-
ease and a more favorable outcome. 
Notably, our ﬁ  ndings show a high proportion of infect-
ed women (52%), including 8 (80%) of the 10 patients who 
died. Previous studies have stressed a male predominance 
(7,9,10,22–25), and have even argued that female sex hor-
mones protect against contracting the disease (26). With V. 
vulniﬁ  cus biotype 3 infections in Israel, it was more likely 
that women purchased and prepared the ﬁ  sh before cook-
ing, and thus were more likely to be exposed to ﬁ  shbone 
injuries.
There are 3 major clinical syndromes of V. vulniﬁ  cus 
illnesses, including primary bacteremia (mostly related to 
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Table 1. Clinical characteristics of patients with Vibrio vulnificus biotype 3 infections, Israel, 1998–2005* 
Clinical characteristics  All patients 
Patients with laboratory-
confirmed infection 
Patients with suspected 
infection p value† 
No. patients studied (%) 132 (100) 94 (100)  38 (100) 
Males, no. (%)  64 (48.5)  40 (42.6)  24 (63.2)  0.036
M:F ratio  0.94:1 0.7:1 1.7:1
Mean age, y; median (range)  58.9; 66 (10–93)  63.1; 68 (10–93)  48.7; 47.5 (11–88)  NS
Clinical presentation 
  Mean incubation time, h; median (range)  17.7; 12 (1–96)  13.9; 12 (0.5–48)  28; 20 (1–96)  <0.001
  Bacteremia, no. (%)  31 (23.5)  31 (33.0)  NA
  Septic shock, no. (%)  11 (8.7)‡  10 (11.0)§  1 (2.9)¶  NS
  Necrotizing fasciitis, no. (%)  16 (12.7)‡  16 (17.6)§  0 0.006
  Uncomplicated cellulitis, no. (%)  92 (69.7)‡  62 (68.1)§  30 (85.7)¶  0.072
  Abscess formation, no. (%)  12 (9.8)‡  7 (7.7)§  5 (14.3)¶  NS
  Peritonitis, no. (%)  1 (0.8)‡  1 (1.1)§  0 NS
Underlying diseases# 
  None, no. (%)  59 (44.7)  49 (52.1)  10 (26.3)  0.007
  Liver disease, no. (%)  18(13.6)  18 (19.1)  0 0.002
  Diabetes mellitus, no. (%)  18 (13.6)  13 (13.8)  5 (13.2)  NS
  Ischemic heart disease, no. (%) 9 (6.8)  8 (8.5)  1 (2.6)  NS
  Altered immune status,** no. (%)  13 (9.8)  9 (9.6)  4 (10.5)  NS
  Hemolytic anemia, no. (%)  3 (2.3)  2 (2.1)  1 (2.6)  NS
Outcome
  Mean hospitalization time, d; median (range)  10.9; 9 (2–50)  12.7; 11 (2–50)  6.2; 5 (2–20)  0.003
  Amputation, no. (%)  9 (6.8)  9 (9.6)  0 0.059
  Death, no. (%)  10 (7.6)  10 (10.6)  0 0.062
No. patients with known fish exposure††  104 72 32
  Tilapia, no. (%)  86 (82.7)  60 (83.3)  26 (81.3)  NS
  Carp, no. (%)  14 (13.5)  10 (13.9)  4 (12.5)  NS
  Tilapia plus carp, no. (%)  2 (1.9)  1 (1.4)  1 (3.1)  NS
  Other, no. (%)  2 (1.9)  1 (1.4)  1 (3.1)  NS
*NA, not available; NS, not significant. 
†For comparison between patients with laboratory-confirmed and suspected infections. 
‡n = 126. 
§n = 91. 
¶n = 35. 
#Patients may have >1 underlying diseases. 
**Due to malignancy or immunosuppressive state. 
††Percentages of exposure to each fish type based on total no. patients with known fish exposure in each category. RESEARCH
raw seafood consumption), wound infection (mostly relat-
ed to immersion in contaminated water or to injury by sea-
food preparation), and gastroenteritis (after consumption 
of seafood or swallowing contaminated water) (9,23,27). 
Patients with primary bacteremia caused by non–biotype 
3 strains are more likely to have predisposing conditions, 
particularly liver diseases in >80% of patients (7–9), 
whereas patients with wound infection are more likely to 
be previously healthy and have a more favorable outcome 
(9,10,23,24,28–30). The death rate may exceed 50% in the 
most seriously ill patients (7–9,23). 
Our study describes a large, uniform group of patients 
who acquired infection through percutaneous exposure. 
All sought treatment for a wound infection, which in 18% 
was complicated by secondary bacteremia. In 38 patients 
(29%), laboratory conﬁ  rmation of infection was lacking. 
These patients tended to delay seeking treatment and to 
have a milder form of infection, compared with patients 
who had laboratory-conﬁ  rmed infection. Some of the pa-
tients who lacked laboratory conﬁ  rmation may not have 
had V. vulniﬁ  cus infection. However, patients with milder 
forms of V. vulniﬁ  cus infection may have been less likely to 
undergo extensive microbiologic workup and the yield of 
cultures, if taken, would have been lower. 
Only 45% of the patients in the group had underlying 
diseases. Liver disease occurred in 14% of patients over-
all, and in 19% of patients with conﬁ  rmed cases, but was 
not a statistically signiﬁ  cant risk factor for death. The case-
fatality rate was 7.6% for the entire study population and 
10.6 % for patients with laboratory-conﬁ  rmed infection. 
These characteristics concur with prior reports of wound 
infection syndrome caused by non–biotype 3 V. vulniﬁ  cus 
(9,10,23,24,27–30).
Of concern is our ﬁ  nding that V. vulniﬁ  cus infection 
was not limited to tilapia exposure. Fourteen persons (13%) 
reported exposure to the common carp, or to both tilapia 
and common carp (2 persons, 2%). Tilapia and common 
carp are co-cultivated in several ﬁ  shponds in northern Is-
rael, which may have resulted in cross-contamination. For 
those exposed to salt water ﬁ  sh (gilt-head sea brim and 
common gray mullet, 1 person each), contamination may 
have occurred at the place of purchase. V. vulniﬁ  cus infec-
tion after exposure to the common carp caused the death 
of 1 patient and the amputation of a ﬁ  nger in another. One 
person infected after exposure to the gilt-head sea brim 
also died. Notably, orthopedic surgeons from hospitals in 
northern Israel have also pointed out severe soft tissue in-
fections, including those caused by V. vulniﬁ  cus, after ﬁ  sh-
bone injury from the common carp (31).
The V. vulniﬁ  cus biotype 3 strains studied were uni-
formly susceptible to all tested antimicrobial agents. These 
results concur with those of similar studies of clinical and 
environmental  V. vulniﬁ  cus biotype 1 isolates from the 
United States (32,33) and Taiwan (22). Only a few isolates 
from Taiwan showed resistance to ceftazidime and moxa-
lactam. 
Molecular subtyping of the V. vulniﬁ  cus biotype 3 
strains by PFGE showed no speciﬁ  c association between 
ﬁ  sh species and PFGE pattern. The results indicate that the 
biotype 3 strains are homogeneous with limited heteroge-
neity between the isolates but cluster distinct from biotype 
1 strains. PFGE has been shown (34) to offer sufﬁ  cient 
discrimination when subtyping biotype 1 strains, but pub-
lished ﬁ  ndings that evaluate the utility of PFGE to sufﬁ  -
ciently discriminate between biotype 3 strains are limited. 
Modiﬁ  cations in restriction sites may alter the number and 
size of DNA fragments, which deﬁ  ne the PFGE pattern and 
result in observable true differences. 
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Table 2. Variables associated with death in laboratory-confirmed Vibrio vulnificus infection, by univariable analysis, Israel, 1998–2005* 
Clinical characteristics  Alive,† n = 84  Dead,† n = 10  p value 
Mean age ± SD, y   62.3 ± 18.2  69.2 ± 15.8  NS
Female, no. (%)  60 (49.2)  8 (80)  NS
Septic shock, no. (%)  41 (4.9)†  6 (60)  <0.001
Bacteremia, no. (%)  24 (28.6)  7 (70)  0.013
Ischemic heart disease, no. (%)  4 (4.8)  4 (40)  0.004
Altered immune status,‡ no. (%)  6 (7.1)  3 (30)  0.052
*NS, not significant. 
†n = 81.   
‡Due to malignancy or immunosuppressive state. 
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Figure 4. Seasonality of Vibrio vulniﬁ  cus biotype 3 illnesses, Israel, 
1998–2005.Molecular Subtyping of V. vulniﬁ  cus, Israel
A high degree of homogeneity among the V. vulniﬁ  cus 
biotype 3 strains and distinction from the biotypes 1 and 2 
has been also observed by other authors applying various 
methods, including random ampliﬁ  ed polymorphic DNA, 
(13), multilocus sequence typing (14,16), and analysis of 
variations in simple sequence repeat loci (35). Notably, the 
latter method was able to demonstrate small-scale varia-
tions among the biotype 3 strains (35). The PFGE results 
also support the conclusion that this biotype 3 is distinct 
from the other V. vulniﬁ  cus biotypes. The high degree of 
homogeneity is another indicator that the emergence of 
biotype 3 is a recent evolutionary event (14,16,36).
We identiﬁ  ed independent risk factors for death in our 
group, including bacteremia, altered immune status, and 
history of ischemic heart disease. Septic shock was also 
found to be a strong predictor of death; however, septic 
shock may also be an outcome variable. Nonetheless, prior 
reports have also identiﬁ  ed septic shock or hypotension 
as important risk factors for death (8,23). A recent large 
study from Taiwan (29) found that treatment with third-
generation cephalosporins combined with tetracycline was 
an independent predictor of lower death rates in a subgroup 
of patients with hemorrhagic bullous necrotic cutaneous le-
sions. We did not demonstrate any correlation between a 
speciﬁ  c antimicrobial drug regimen and death rate in our 
study population. The predisposing diseases that were as-
sociated with death in previous reports were liver disease 
and neutropenia (8,23). Ischemic heart disease was not pre-
viously recognized as a classic predisposing factor predict-
ing death; however, in the Vibrio-associated wound infec-
tions after Hurricane Katrina in Louisiana, USA, ischemic 
heart disease occurred in 7 of 13 patients (54%) with more 
severe illness (25).
Before the introduction of V. vulniﬁ  cus biotype 3 into 
the ﬁ  sh aquaculture no infections were reported in Israel 
(37). Also, no reports have been made of V. vulniﬁ  cus 
infection acquired through marine activities in the Medi-
terranean Sea. Almost the entire impact of V. vulniﬁ  cus 
infections in Israel is associated with the freshwater ﬁ  sh in-
dustry. In response to the new threat, the Israeli Ministry of 
Health has issued regulations forbidding the selling of live, 
uncleaned tilapia (11,38). Fish stores and ﬁ  shpond workers 
have been instructed to use protective gloves when han-
dling ﬁ  sh, to keep fresh ﬁ  sh packed in ice, and to prevent 
direct contact between buyers and live ﬁ  sh. The public has 
been instructed accordingly. Apparently, compliance with 
these regulations is not universal.  
Our ﬁ  ndings outline the substantial effects of V. vul-
niﬁ  cus illnesses in Israel and support a call for more strict 
regulations of fresh ﬁ  sh marketing as well as public educa-
tion. Research efforts should focus on how V. vulniﬁ  cus has 
penetrated the freshwater aquaculture in Israel and ways in 
which this trend can be reversed.  
Dr Zaidenstein is an infectious diseases consultant at Assaf 
Harofeh Medical Center, Zeriﬁ  n, Israel. Her recent research inter-
est is the epidemiology of nosocomial and zoonotic infections.
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